Scarica l'app Stockscreener
110.17
1.75%
1.89
Pre-mercato:
110.25
0.08
+0.07%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché GILD Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Precedente Chiudi:
$108.28
Aprire:
$108.4
Volume 24 ore:
4.49M
Relative Volume:
0.56
Capitalizzazione di mercato:
$137.04B
Reddito:
$28.73B
Utile/perdita netta:
$5.97B
Rapporto P/E:
23.19
EPS:
4.75
Flusso di cassa netto:
$9.84B
1 W Prestazione:
+1.02%
1M Prestazione:
+1.54%
6M Prestazione:
+18.41%
1 anno Prestazione:
+52.15%
Intervallo 1D:
$108.06
$110.97
Intervallo di 1 settimana:
$107.75
$110.97
Portata 52W:
$70.78
$119.96
Gilead Sciences Inc Stock (GILD) Company Profile
Nome
Gilead Sciences Inc
Settore
Industria
Telefono
(650) 574-3000
Indirizzo
333 LAKESIDE DR, FOSTER CITY, CA
Confronta GILD con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
GILD
Gilead Sciences Inc
|
110.17 | 135.66B | 28.73B | 5.97B | 9.84B | 4.75 |
|
LLY
Lilly Eli Co
|
776.44 | 692.83B | 49.00B | 11.11B | -1.27B | 12.29 |
|
JNJ
Johnson Johnson
|
167.93 | 373.35B | 90.63B | 22.66B | 18.57B | 9.35 |
|
ABBV
Abbvie Inc
|
187.11 | 329.24B | 57.37B | 4.20B | 15.39B | 2.35 |
|
NVS
Novartis Ag Adr
|
116.83 | 231.66B | 55.19B | 13.65B | 16.81B | 6.86 |
|
NVO
Novo Nordisk Adr
|
66.78 | 298.68B | 43.59B | 15.04B | 10.74B | 3.3766 |
Gilead Sciences Inc Stock (GILD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-04-22 | Ripresa | Cantor Fitzgerald | Overweight |
| 2025-03-04 | Reiterato | Oppenheimer | Outperform |
| 2025-02-18 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-13 | Aggiornamento | DZ Bank | Hold → Buy |
| 2025-01-10 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2024-12-10 | Ripresa | BofA Securities | Buy |
| 2024-11-15 | Iniziato | Wolfe Research | Outperform |
| 2024-11-14 | Iniziato | Citigroup | Buy |
| 2024-11-08 | Downgrade | Maxim Group | Buy → Hold |
| 2024-10-21 | Aggiornamento | Leerink Partners | Market Perform → Outperform |
| 2024-10-17 | Iniziato | Bernstein | Outperform |
| 2024-10-07 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2024-07-08 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2024-05-01 | Reiterato | Maxim Group | Buy |
| 2024-04-24 | Aggiornamento | HSBC Securities | Reduce → Hold |
| 2024-02-22 | Downgrade | Truist | Buy → Hold |
| 2023-11-09 | Iniziato | Deutsche Bank | Hold |
| 2023-09-08 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2023-09-06 | Iniziato | HSBC Securities | Reduce |
| 2023-07-24 | Reiterato | Barclays | Equal Weight |
| 2023-05-16 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-28 | Ripresa | Piper Sandler | Overweight |
| 2023-01-03 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2022-12-13 | Ripresa | BofA Securities | Neutral |
| 2022-12-09 | Downgrade | DZ Bank | Buy → Hold |
| 2022-10-31 | Aggiornamento | Barclays | Underweight → Equal Weight |
| 2022-10-28 | Reiterato | BMO Capital Markets | Market Perform |
| 2022-10-28 | Reiterato | Cowen | Outperform |
| 2022-10-28 | Reiterato | JP Morgan | Overweight |
| 2022-10-28 | Reiterato | Jefferies | Buy |
| 2022-10-28 | Aggiornamento | Piper Sandler | Neutral → Overweight |
| 2022-10-28 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-10-28 | Aggiornamento | Truist | Hold → Buy |
| 2022-10-28 | Reiterato | Wells Fargo | Equal Weight |
| 2022-10-04 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2022-07-13 | Iniziato | Cantor Fitzgerald | Neutral |
| 2022-05-23 | Iniziato | SVB Leerink | Mkt Perform |
| 2022-02-28 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2022-02-02 | Reiterato | BMO Capital Markets | Outperform |
| 2022-02-02 | Reiterato | BofA Securities | Neutral |
| 2022-02-02 | Reiterato | RBC Capital Mkts | Outperform |
| 2022-02-02 | Reiterato | Truist | Hold |
| 2022-02-02 | Reiterato | Wells Fargo | Equal Weight |
| 2022-01-28 | Aggiornamento | Argus | Hold → Buy |
| 2022-01-06 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-12-09 | Ripresa | Wells Fargo | Equal Weight |
| 2021-12-06 | Iniziato | Goldman | Neutral |
| 2021-11-19 | Aggiornamento | BMO Capital Markets | Market Perform → Outperform |
| 2021-11-19 | Ripresa | Piper Sandler | Neutral |
| 2021-10-20 | Ripresa | Cowen | Outperform |
| 2021-07-30 | Reiterato | BMO Capital Markets | Market Perform |
| 2021-07-30 | Reiterato | RBC Capital Mkts | Outperform |
| 2021-04-01 | Aggiornamento | Bernstein | Mkt Perform → Outperform |
| 2021-03-30 | Aggiornamento | Redburn | Neutral → Buy |
| 2021-01-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2021-01-04 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2020-11-03 | Ripresa | Morgan Stanley | Equal-Weight |
| 2020-10-28 | Iniziato | UBS | Neutral |
| 2020-09-30 | Ripresa | Jefferies | Buy |
| 2020-09-15 | Aggiornamento | Maxim Group | Hold → Buy |
| 2020-07-31 | Reiterato | Credit Suisse | Neutral |
| 2020-07-31 | Reiterato | Morgan Stanley | Equal-Weight |
| 2020-07-31 | Reiterato | Piper Sandler | Overweight |
| 2020-07-31 | Reiterato | RBC Capital Mkts | Outperform |
| 2020-07-31 | Reiterato | SunTrust | Hold |
| 2020-07-31 | Reiterato | Wells Fargo | Equal Weight |
| 2020-07-20 | Aggiornamento | Credit Suisse | Underperform → Neutral |
| 2020-06-03 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2020-05-26 | Aggiornamento | SunTrust | Sell → Hold |
| 2020-05-01 | Downgrade | JP Morgan | Overweight → Neutral |
| 2020-05-01 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2020-05-01 | Downgrade | SunTrust | Hold → Sell |
| 2020-04-27 | Downgrade | UBS | Buy → Neutral |
| 2020-04-20 | Downgrade | BMO Capital Markets | Outperform → Market Perform |
| 2020-04-20 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| 2020-04-17 | Downgrade | CFRA | Hold → Sell |
Mostra tutto
Gilead Sciences Inc Borsa (GILD) Ultime notizie
What To Expect From Gilead Sciences’ Q2 2025 Earnings Report - Barchart.com
Gilead Sciences (GILD) Beats Stock Market Upswing: What Investors Need to Know - Yahoo Finance
Lobbying Update: $1,700,000 of GILEAD SCIENCES INC lobbying was just disclosed - Quiver Quantitative
Gilead and Arcus Biosciences’ Promising Phase 3 Lung Cancer Study Update - TipRanks
Gilead’s Lenacapavir Up For EMA Verdict Amid Packed CHMP Meeting Agenda - insights.citeline.com
What analysts say about Gilead Sciences Inc. stockSignificant capital appreciation - jammulinksnews.com
What drives Gilead Sciences Inc. stock priceBreakthrough investment results - jammulinksnews.com
After Gilead Deal, Hookipa Hangs Up Its Hat - insights.citeline.com
Gilead Sciences (GILD) Reaches Deal to Offer HIV Vaccine to Low and Middle-Income Nations - MSN
Hookipa, having sold off vaccines to Gilead, opts to wind down - Fierce Biotech
Gilead Sciences Inc. Stock Analysis and ForecastMarket-leading growth rates - jammulinksnews.com
Gilead’s HIV Strength Drives Gains, But Pipeline Is Key - Finimize
Why Gilead Sciences (GILD) Appeals to Income Investors in the Pharma Sector - MSN
Is Gilead Sciences Inc. a good long term investmentFree Wealth Planning Blueprint - Jammu Links News
Lobbying Update: $90,000 of GILEAD SCIENCES INC. lobbying was just disclosed - Quiver Quantitative
Gilead Sciences Trading Volume Surges 54.53% to $720 Million Ranking 154th in Market Activity - AInvest
HOOKIPA Pharma Inc. Announces Intent to Voluntarily Delist from Nasdaq and Pursue Asset Sale with Gilead Sciences - Quiver Quantitative
HOOKIPA Pharma Exits Nasdaq Market as Gilead Sciences Acquires Key Drug Programs - Stock Titan
Foster City drugs giant Gilead to pay $202 million over alleged kickback scheme - SiliconValley.com
Pennsylvania to receive $1.2M from Gilead over kickback scheme to promote HIV drugs - WPXI
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know - MSN
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Gilead Sciences, Inc.GILD - PR Newswire
Attorney General Ellison helps secure $200M from Gilead for paying illegal kickbacks - Red Lake Nation News
Gilead Sciences Inc. Agrees to $202 Million Settlement Over Kickbacks, Illinois Leads Charge with Multi-State Coalition - Hoodline
Gilead To Pay $202 Million In Nationwide Settlement Over Illegal HIV Drug Kickback Scheme - MyChesCo
Gilead Sciences CFO Dickinson sells $277k in stock - Investing.com
Gilead reaches $202M settlement over kickback scheme to promote HIV drug - Crain's New York Business
Troy Griffin on Gilead’s mission at Chosen Few picnic - rollingout.com
Why Merck Is A Better Dividend Stock Than Gilead Sciences (NYSE:MRK) - Seeking Alpha
Nevada to receive over $440K from Gilead settlement over alleged illegal kickbacks - KTVN
Gilead Sciences Advances in Triple-Negative Breast Cancer Treatment - TipRanks
Minnesota and Iowa join $202M Gilead settlement over kickbacks - KIMT
New York AG Letitia James Clinches Monumental $202M Victory Against Gilead Sciences Over HIV Med Kickbacks - Hoodline
Attorney General Raoul Announces More Than $200 Million Settlement With Gilead Sciences Over Illegal Kickbacks To Providers For Prescriptions - RiverBender.com
Pennsylvania to Receive Over $1.2 Million in HIV Drug Kickback Settlement with Gilead - Franklin County Free Press
AG Sunday Part of National Coalition Securing $200M+ from Gilead Sciences for Illegal Kickback Scheme to Sell HIV Drugs - exploreJefferson
GILD Investors Have Opportunity to Join Gilead Sciences, Inc. Fraud Investigation with the Schall Law Firm - PR Newswire
Gilead’s Vítor Papão on key partnerships and the role of tech in public health - Gulf Business
Attorney General Bonta Helps Secure Over $200 Million from Gilead Sciences for Paying Illegal KickbacksState of California - State of California - Department of Justice (.gov)
Here's Why Gilead Sciences (GILD) Fell More Than Broader Market - Yahoo Finance
Tamar Braxton partners with Gilead for HIV awareness - Rolling Out
Sector Update: Health Care - MarketScreener
Pennsylvania to receive $1.28 million in settlement over Gilead’s illegal HIV drug kickback scheme - WTAJ
Tamar Braxton & Gilead Partner For PrEP Promo To Black Women - Black America Web
Gilead Sciences Reaches $202 Million Settlement Over Kickback Scheme Promoting HIV Drugs - MarketScreener
Pennsylvania Part of National Coalition Securing $200M+ from Gilead Sciences for Illegal Kickback Scheme to Sell HIV Drugs - pennwatch.org
Pennsylvania expected to get $1.28 million from biopharma company for violating anti-kickback laws - ABC27
Massachusetts Secures $1.6 Million from Gilead in $202 Million Multi-State Settlement Over HIV Drug Kickbacks - Hoodline
Gilead reaches $202M settlement over HIV drug speaker program - Seeking Alpha
Tamar Braxton Partners with Gilead to Empower Black Women on HIV Prevention - ThisisRnB.com
Bernstein Maintains Buy Rating on Gilead Sciences (GILD) Stock - Insider Monkey
Gilead Sciences Inc Azioni (GILD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Gilead Sciences Inc Azioni (GILD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Dickinson Andrew D | Chief Financial Officer |
Jul 15 '25 |
Sale |
111.03 |
2,500 |
277,575 |
162,610 |
3.63%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):